Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a biotechnology company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. This news page aggregates company announcements, clinical updates, regulatory developments, and financial disclosures related to Iovance’s TIL platform and commercial activities.
Readers can find news about Amtagvi, which Iovance describes as the first FDA-approved T cell therapy for a solid tumor indication, as well as updates on its use in advanced melanoma and other solid tumors. Coverage includes information on Health Canada’s conditional approval of Amtagvi for certain patients with unresectable or metastatic melanoma, and ongoing work to expand access through treatment centers and international markets.
The feed also features interim data from key clinical trials, such as registrational Phase 2 studies of lifileucel in advanced non-small cell lung cancer and other solid tumors, along with reports on next-generation programs like gene-edited TIL therapies and modified IL-2 analogs. Corporate news items include quarterly financial result announcements, conference presentations, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and capital markets transactions described in SEC filings.
Investors, analysts, and healthcare professionals can use this page to follow how Iovance communicates progress on its TIL pipeline, commercial execution for Amtagvi and Proleukin, and interactions with regulators. Regularly reviewing these updates provides context on the company’s development trajectory and its efforts to advance TIL-based immuno-oncology therapies.
Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in TIL therapies for cancer patients, has granted inducement stock options to 59 new non-executive employees. The grants, approved on May 15, 2025, cover 278,770 shares of common stock with an exercise price of $1.76 per share. These options were awarded under the company's Amended and Restated 2021 Inducement Plan, following Nasdaq Listing Rule 5635(c)(4).
The stock options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining shares vesting quarterly over the following two years, contingent on continued employment.
[ "Expansion of workforce with 59 new employees indicates company growth", "Structured vesting schedule helps retain talent over a 3-year period", "Stock options align employee interests with company performance" ]Iovance Biotherapeutics (NASDAQ: IOVA), a biotech company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has scheduled its first quarter 2025 financial results and corporate updates webcast for Thursday, May 8, 2025, at 4:30 p.m. ET. The company's management will host a conference call and live audio webcast to discuss the quarterly results and provide business updates. Investors and interested parties can access the webcast through the company's website at IR.Iovance.com or by registering directly at the provided link. The webcast recording will remain available for one year after the event.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced its participation in two major scientific conferences, showcasing significant developments in their TIL therapy pipeline. At the 2025 AACR Annual Meeting (April 25-30), the company will present pre-clinical data for IOV-5001, their novel genetically engineered IL-12 TIL cell therapy.
At the 2025 ASCO Annual Meeting (May 30-June 3), Iovance will present two key studies: five-year outcomes data from the C-144-01 study of lifileucel monotherapy in advanced melanoma patients, and a poster on lifileucel's study design for frontline advanced non-small cell lung cancer treatment.
The company will also host a panel discussion with melanoma experts on May 31, 2025, at 6 PM CDT, with both live and archived webcasts available on their website.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for new employees on April 17, 2025. The grants cover 297,600 shares of common stock, distributed among fifty new, non-executive employees. The options were issued under the company's Amended and Restated 2021 Inducement Plan, with an exercise price of $3.06 per share, matching the closing price on the grant date.
The stock options feature a three-year vesting schedule, with one-third vesting on the first employment anniversary and the remaining portions vesting in eight quarterly installments over the following two years, contingent on continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for new employees on March 20, 2025. The company granted options covering 308,710 shares of common stock to 43 new, non-executive employees under its Amended and Restated 2021 Inducement Plan.
The stock options were granted with an exercise price of $3.54, matching the closing price of Iovance's common stock on the grant date. The vesting schedule spans three years, with one-third of shares vesting on the first employment anniversary and the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) reported strong financial results for Q4 and FY2024. Total product revenue reached $73.7M in Q4 and $164.1M in FY24, hitting the upper end of guidance. The company's flagship product Amtagvi generated $48.7M in Q4 and $103.6M in FY24 revenue, while Proleukin contributed $25.0M in Q4 and $60.5M in FY24.
The company reaffirmed its FY25 revenue guidance of $450M-$475M and expects cash burn under $300M. With approximately $422M in cash as of February 2025, Iovance is funded into H2 2026. The company anticipates 2025 regulatory approvals for Amtagvi in the UK, EU, and Canada.
Q4 2024 net loss was $78.6M ($0.26/share), improved from $116.4M ($0.45/share) in Q4 2023. FY24 net loss was $372.2M ($1.28/share), better than $444.0M ($1.89/share) in FY23.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement stock options for 71 new, non-executive employees on February 21, 2025. The grants cover 328,730 shares of common stock, with an exercise price of $5.78 per share, matching the closing price on the grant date.
The awards were issued under the company's Amended and Restated 2021 Inducement Plan, which was last updated on November 22, 2024. The stock options follow a three-year vesting schedule: one-third vests on the first employment anniversary, with the remaining shares vesting in eight quarterly installments over the following two years, contingent on continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA), a biotechnology company specializing in novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has scheduled its fourth quarter and full year 2024 financial results announcement for February 27, 2025.
The company will host a live audio webcast at 4:30 p.m. EST on the same day to discuss results and provide corporate updates. Additionally, Iovance will participate in two upcoming healthcare conferences: TD Cowen's 45th Annual Health Care Conference on March 3, 2025, and Barclays 27th Annual Global Healthcare Conference on March 13, 2025.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced the approval of inducement grants for its new Chief Commercial Officer, Daniel Kirby. The grants include stock options and restricted stock units covering up to 305,000 shares of common stock, approved on February 10, 2025.
The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, with stock options exercise price set at the closing price on the grant date. The vesting schedule spans three years, with one-third vesting on the first anniversary and the remaining shares vesting in eight quarterly installments over two years. Some restricted stock awards may vest based on performance milestones tied to financial results rather than time-based vesting.
FAQ
What is the current stock price of Iovance Biotherp (IOVA)?
What is the market cap of Iovance Biotherp (IOVA)?
